Human Tissue Models for Better Therapies
MIMETAS (mimetas.com) scores 82 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, Technology brands, Other brands, in the 84th percentile of 16750 Healthcare brands.
MIMETAS is a company based in Leiden, Netherlands, founded in 2013. It develops the OrganoPlate platform, an organ-on-a-chip technology that creates scalable, multiplexed human tissue models for drug discovery and safety testing. The company's stated mission is to recreate human tissues with precision to enable faster, more reliable research while reducing reliance on animal testing. Its target audience includes pharmaceutical and biotech companies and researchers working in fields such as immunology, oncology, metabolic disease, neurology, and toxicology.
| Brand Name | MIMETAS |
|---|---|
| Domain | mimetas.com |
| Industry | Healthcare, Technology |
| Founded | 2013 |
| Headquarters | Leiden |
| Main Competitors | Emulate, CN Bio Innovations (79/100), TissUse (77/100), Hesperos (56/100), InSphero (77/100), AlveoliX (74/100), Nortis Bio |
Moz Domain Authority 42/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #2,077,931 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
MIMETAS has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Explore MIMETAS" (Meta description too short (2 words). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, Webflow, HubSpot.
Social footprint: verified profiles on LinkedIn, X (Twitter), YouTube, Facebook, Instagram, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is MIMETAS?", Claude could identify the brand as of October 2026. MIMETAS is a Dutch life sciences company that develops organ-on-a-chip technology, best known for its OrganoPlate platform, which allows researchers to grow 3D tissue and organ models for drug discovery and toxicology testing. Best known for the OrganoPlate organ-on-a-chip platform for 3D cell culture and drug testing.
When asked "Best brands similar to MIMETAS?", Claude would recommend MIMETAS as of October 2026. It's a recognized player in the organ-on-a-chip space, so it would come up alongside companies like Emulate or TissUse when discussing microphysiological systems for drug development.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
MIMETAS's main competitors in Healthcare: CN Bio Innovations (79/100), TissUse (77/100), Hesperos (56/100), InSphero (77/100), AlveoliX (74/100).
Sources: Brand Analyzer scan
MIMETAS offers the OrganoPlate platform, which enables scalable, multiplexed modeling of human tissue physiology. This technology is used for drug discovery and safety testing applications across fields including immunology, oncology, metabolic disease, neurology, and ADME/toxicology.
Sources: MIMETAS official site
MIMETAS is a biotechnology company headquartered in Leiden, Netherlands, founded in 2013. It specializes in organ-on-a-chip technology, developing platforms that recreate human tissue physiology for use in drug discovery and safety testing.
Sources: MIMETAS official site
MIMETAS has moderate AI-search visibility, scoring 52/100 on Brand Analyzer's AI visibility composite (visibility 63, trust 26, recommendation 65). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: MIMETAS official site
MIMETAS was founded in 2013. MIMETAS operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
MIMETAS is headquartered in Leiden. MIMETAS operates in the Healthcare category.
Sources: Wikidata
MIMETAS develops and provides the OrganoPlate platform, a technology that creates scalable, multiplexed human tissue models used to study disease biology and test drug safety and efficacy. These models aim to provide more predictive data than traditional methods while reducing the need for animal experiments.
Sources: MIMETAS official site
MIMETAS scores 65/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: MIMETAS official site
MIMETAS is known for its OrganoPlate platform, a leading organ-on-a-chip technology that enables researchers to model human tissue physiology at scale for pharmaceutical research and toxicology testing.
Sources: MIMETAS official site
MIMETAS can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: MIMETAS official site
MIMETAS's platform is used by pharmaceutical and biotech companies, as well as researchers and scientists involved in drug discovery, safety testing, and disease biology research across fields such as immunology, oncology, metabolic disease, neurology, and toxicology.
Sources: MIMETAS official site
MIMETAS scores 52/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
MIMETAS has a limited AI-visibility profile at 52/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (65/100) and its weakest is trust (26/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #2,077,931 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify MIMETAS from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to MIMETAS: Milliman MedInsight (82/100), Micronit (82/100), mindbodygreen (82/100), Mindbody (82/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.